In a randomized, open-label study of pregnant women with PGDM, there were less gestational hypertension (p = 0.029) and maternal weight gain (p < 0.001) in the MET-treated group compared to the insulin-treated group (Ainuddin et al., 2015). This evidence concerns the gene INS and preeclampsia.